Health Care • Biotechnology: Pharmaceutical Preparations
$0.93 ▼ -0.04
(-3.99%)
MKT CAP: $6.3M • VOL: 18.1K
52W L $1 52W H $10
ROARABLE / RQD
D- • 40/100
PIOTROSKI
2 / 9
FBLG // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$16.6M | -$13.7M | -$8.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$18.6M | -$11.2M | -$16.5M |
| EBITDA (Normalized) | -$16.4M | -$13.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$16.4M | -$11.9M | -$6.4M |
| Capital Expenditures (CapEx) | $262.0K | $184.0K | — |
| Free Cash Flow (FCF) | -$16.7M | -$12.1M | -$6.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.9M | $14.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $6.2M | $2.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FBLG.